Alana Rogne
Psychiatric/Mental Health · Reno, NVNPI 1215577788
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 271 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 37.6% of the total. 2025 is the largest year on record at $2,288, 3.5 times the $648 reported in 2021. Among psychiatric/mental health clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 271 payments — averaging $22.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$806
- Teva Pharmaceuticals USA, Inc.$591
- Neurocrine Biosciences, Inc.$576
- Otsuka America Pharmaceutical, Inc.$523
- Vanda Pharmaceuticals Inc.$297
- plus $1K from 19 others
What the payments were for
- Food & beverage$5,90597%
- Education$1833%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 97 | $2,290 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 49 | $806 |
| Teva Pharmaceuticals USA, Inc. | 22 | $591 |
| Neurocrine Biosciences, Inc. | 19 | $576 |
| Otsuka America Pharmaceutical, Inc. | 29 | $523 |
| Vanda Pharmaceuticals Inc. | 11 | $297 |
| Alkermes, Inc. | 10 | $224 |
| E.r. Squibb & Sons, L.L.C. | 3 | $173 |
| Indivior Inc. | 5 | $137 |
| Eisai Inc. | 4 | $65 |
| Sunovion Pharmaceuticals Inc. | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Luye Pharma (USA) Ltd. | 2 | $35 |
| Corium, LLC | 2 | $35 |
| Pfizer | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Amgen | 1 | $26 |
| Ironshore Pharmaceuticals Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Merck | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Johnson & Johnson | 1 | $13 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,088 in reported general payments places this provider in the 90th percentile of 362 psychiatric/mental health providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QuviviqDaridorexant Hcl | 19 | $11,158 |
| BelsomraSuvorexant | 18 | $7,820 |
| Quetiapine Fumarate | 26 | $345 |
| Trazodone Hcl | 16 | $324 |
| Olanzapine | 11 | $164 |
| Gabapentin | 12 | $136 |
| Alprazolam | 17 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Idorsia Pharmaceuticals US IncQuviviq | $19 | $11,15819 claims |
| MerckBelsomra | $18 | $7,82018 claims |
| Lilly USA, LLCOlanzapine | $18 | $16411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 362 psychiatric/mental health providers in Nevada.
Other psychiatric/mental health in Reno
- Okechukwu OlisaReno$7K
- Kaiwen JiangReno$6K
- Doris AnukamReno$5K
- Megan SeivertReno$4K
- Denis WilliamsReno$4K
- Nathanael MellumReno$3K
- Jacqueline WilliamsReno$3K
- Michelle GiddingsLas Vegas$131K
- Patrick ApiladoLas Vegas$19K
- Joshua HamiltonLas Vegas$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.